| A4T |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| D12E |
Letermovir |
1.40 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| G16A |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| E17A |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| E17del |
Letermovir |
1.30 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| Q23K |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| D24G |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| S28F |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| E39D |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| D40N |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| E42G |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| G56D |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| G61D |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| L70I |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| P91S |
Letermovir |
2.10 |
Low level resistance
|
Details |
A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017) |
| A95V |
Letermovir |
13.80 |
High level resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| V113L |
Letermovir |
1.50 |
No resistance
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
| S153P |
N/A |
N/A |
Natural polymorphism
|
Details |
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure. (Aug 2022) |
